Delving into the Latest Updates on LAT-010 with Synapse

Overview

Basic Info

Drug Type

Cytokines

Synonyms

LAT-010

Target

IL-2Rβγ

Mechanism

IL-2Rβγ agonists(Interleukin-2 Rβγ agonists)

Therapeutic Areas

NeoplasmsDigestive System DisordersEndocrinology and Metabolic Disease+ [3]

Active Indication

Breast CancerColorectal CancerHepatocellular Carcinoma+ [7]

Inactive Indication-

Originator Organization

Latticon Antibody Therapeutics, Inc

Active Organization

Laitekang (Suzhou) Biopharmaceutical Co., Ltd.Latticon Antibody Therapeutics, Inc

Inactive Organization-

Drug Highest PhasePhase 1/2

First Approval Date-

Regulation-

Login to view timeline

This is an open-label, multicenter, Phase 1/2, first-in-human (FIH), dose-escalation and cohort-expansion study of LAT010 to evaluate the safety, tolerability, immunogenicity, PK, PD, and antitumor activity in patients with advanced solid tumors. The study consists of 2 parts: Phase 1 dose-escalation and Phase 2 cohort expansion.

Start Date05 Jun 2024

Sponsor / Collaborator

Latticon Antibody Therapeutics, Inc

CTR20244740

/ Not yet recruitingPhase 1/2

评估LAT010在中国局部晚期或转移性实体瘤受试者中的安全性、耐受性、药代动力学/药效学、免疫原性和抗肿瘤活性的I/II期临床研究

[Translation] Phase I/II clinical study to evaluate the safety, tolerability, pharmacokinetics/pharmacodynamics, immunogenicity and anti-tumor activity of LAT010 in Chinese subjects with locally advanced or metastatic solid tumors

评估LAT010单药治疗在局部晚期或转移性实体瘤受试者中的安全性和耐受性。

[Translation]

To evaluate the safety and tolerability of LAT010 monotherapy in subjects with locally advanced or metastatic solid tumors.

Start Date-

Sponsor / Collaborator

Laitekang (Suzhou) Biopharmaceutical Co., Ltd.

100 Clinical Results associated with LAT-010

Login to view more data

100 Translational Medicine associated with LAT-010

Login to view more data

100 Patents (Medical) associated with LAT-010

Login to view more data

100 Deals associated with LAT-010

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Breast Cancer	Phase 2	US	Laitekang (Suzhou) Biopharmaceutical Co., Ltd.	13 Dec 2024
Breast Cancer	Phase 2	CN	Laitekang (Suzhou) Biopharmaceutical Co., Ltd.	13 Dec 2024
Colorectal Cancer	Phase 2	US	Laitekang (Suzhou) Biopharmaceutical Co., Ltd.	13 Dec 2024
Colorectal Cancer	Phase 2	CN	Laitekang (Suzhou) Biopharmaceutical Co., Ltd.	13 Dec 2024
Hepatocellular Carcinoma	Phase 2	US	Laitekang (Suzhou) Biopharmaceutical Co., Ltd.	13 Dec 2024
Hepatocellular Carcinoma	Phase 2	CN	Laitekang (Suzhou) Biopharmaceutical Co., Ltd.	13 Dec 2024
Non-Small Cell Lung Cancer	Phase 2	US	Laitekang (Suzhou) Biopharmaceutical Co., Ltd.	13 Dec 2024
Non-Small Cell Lung Cancer	Phase 2	CN	Laitekang (Suzhou) Biopharmaceutical Co., Ltd.	13 Dec 2024
Ovarian Cancer	Phase 2	US	Laitekang (Suzhou) Biopharmaceutical Co., Ltd.	13 Dec 2024
Ovarian Cancer	Phase 2	CN	Laitekang (Suzhou) Biopharmaceutical Co., Ltd.	13 Dec 2024